What question did this study set out to answer?

The aim is to evaluate the efficacy and safety of first-line tislelizumab plus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma.

April 3, 2026EsophagusOpen Access

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the efficacy and safety of first-line tislelizumab plus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma.
Subgroup analysis of Japanese patients from the RATIONALE-306 study
Administration of tislelizumab in combination with chemotherapy
Evaluation of outcomes over a follow-up period of three years
Tislelizumab plus chemotherapy showed sustained efficacy after three years
Safety profile was found to be tolerable in the Japanese subgroup
Results are consistent with the global RATIONALE-306 population findings

Implication

First-line tislelizumab plus chemotherapy shows efficacy in advanced esophageal squamous cell carcinoma, suggesting a viable treatment option for patients.

Abstract

After 3 years, first-line tislelizumab plus chemotherapy demonstrated sustained efficacy and a tolerable safety profile in Japanese patients with unresectable locally advanced/metastatic ESCC, consistent with the global RATIONALE-306 population.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ogata et al. (2026) studied this question.

synapsesocial.com/papers/69cf5dd55a333a821460bdd9 https://doi.org/10.1007/s10388-026-01199-y

View Full Paper

Ask AI

Bookmark

Implication

First-line tislelizumab plus chemotherapy shows efficacy in advanced esophageal squamous cell carcinoma, suggesting a viable treatment option for patients.

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up

Key Points

Implication

Abstract

Discussion

Cite This Study

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading